Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis

[1]  R. Corvò,et al.  Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  W. Shi,et al.  Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck , 2016, American journal of clinical oncology.

[3]  T. Strom,et al.  Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer. , 2015, Oral oncology.

[4]  James D. Murphy,et al.  Concurrent cetuximab versus platinum‐based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer , 2015, Head & neck.

[5]  R. Shi,et al.  Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review , 2015, Clinical Medicine Insights. Oncology.

[6]  Hushan Yang,et al.  Current management of locally advanced head and neck cancer: the combination of chemotherapy with locoregional treatments. , 2014, Seminars in oncology.

[7]  S. Barni,et al.  Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. , 2014, Oral oncology.

[8]  W. Shi,et al.  Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC). , 2014, Oral oncology.

[9]  Sue S Yom,et al.  Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Srinivasan Vijayakumar,et al.  Comparison of Cisplatin Versus Cetuximab With Intensity Modulated Radiation Therapy in Locally Advanced Squamous Cell Carcinomas of Head and Neck: Toxicity, Patterns of Failure, and Survival Analysis , 2014 .

[11]  Ming-Huang Chen,et al.  Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment , 2014, BioMed research international.

[12]  J. Bourhis,et al.  Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas , 2014, Strahlentherapie und Onkologie.

[13]  N. Lee,et al.  Multi-institution Analysis of Concurrent Chemoradiation Therapy With Cisplatin (CDDP) Versus Cetuximab (C225) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-HNSCC): Can HPV Help Decide Which Agent?: Definitive Management of Head-and-Neck Squamous Cell Carcinoma , 2014 .

[14]  Xuelei Ma,et al.  Epidermal growth factor receptor could play a prognostic role to predict the outcome of nasopharyngeal carcinoma: A meta-analysis. , 2014, Cancer biomarkers : section A of Disease markers.

[15]  A. Baschnagel,et al.  A matched-pair comparison of intensity-modulated radiation therapy with cetuximab versus intensity-modulated radiation therapy with platinum-based chemotherapy for locally advanced head neck cancer , 2014, International Journal of Clinical Oncology.

[16]  K. Trinkaus,et al.  Cisplatin versus Cetuximab Given Concurrently with Definitive Radiation Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma , 2013, Oncology.

[17]  R. Orecchia,et al.  A Phase 2-3 Study Comparing Concomitant Chemoradiation Therapy (CRT) Versus Cetuximab/RT (CET/RT) With or Without Induction Docetaxel/Cisplatin/5-Fluorouracil (TPF) in Locally-Advanced Head and Neck Squamous Cell Carcinoma (LASCCHN) – Efficacy Results of the GSTTC Italian Study (NCT01086826) , 2013 .

[18]  N. Lee,et al.  Multi-institution Analysis of Concurrent Chemoradiation Therapy With Cisplatin (CDDP) Versus Cetuximab (C225) in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck (LA-HNSCC): Can HPV Help Decide Which Agent? , 2013 .

[19]  Jonn Wu,et al.  Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab. , 2013, Journal of cancer research and therapeutics.

[20]  Richard Pazdur,et al.  Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. , 2013, The oncologist.

[21]  G. Calais,et al.  Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Chabaud,et al.  Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients , 2013, Anti-cancer drugs.

[23]  C. Terhaard,et al.  Outcome and toxicity of radiotherapy combined with chemotherapy or cetuximab for head and neck cancer: Our experience in one hundred and twenty‐five patients , 2013, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[24]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[25]  J. M. Jerez,et al.  Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer , 2013, BMC Cancer.

[26]  S. Yom,et al.  EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab , 2012, Chemotherapy research and practice.

[27]  G. Poissonnet,et al.  Induction TPF followed by chemoradiation or radiotherapy-cetuximab in nonresectable advanced head and neck squamous cell carcinoma: A retrospective study in 164 patients. , 2012 .

[28]  J. Shah,et al.  Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. , 2011, International journal of radiation oncology, biology, physics.

[29]  W. Weichert,et al.  Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN) , 2011, Radiation oncology.

[30]  L. Sequist,et al.  Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  G. Giaccone,et al.  American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  F. Wrba,et al.  Survival of patients with HPV-positive oropharyngeal cancer after radiochemotherapy is significantly enhanced , 2011, Wiener klinische Wochenschrift.

[34]  M. Shah,et al.  Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Corvò,et al.  Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  D. Hollywood,et al.  Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  N. Lee,et al.  Cisplatin (CDDP) and Radiation (RT) versus Cetuximab (C) and RT in the Context of Human Papillomavirus (HPV) and P16 in the Treatment of Locally Advanced Head and Neck Cancer (LAHNC) , 2010 .

[38]  S. Lippman,et al.  Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC) , 2010, Head & neck oncology.

[39]  Jordi Giralt,et al.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.

[40]  S. Galper,et al.  Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC). , 2016, Journal of Clinical Oncology.

[41]  N. Lee,et al.  Severe Radiation Dermatitis in Patients With Locally Advanced Head and Neck Cancer Treated With Concurrent Radiation and Cetuximab , 2009, American journal of clinical oncology.

[42]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[43]  C. Chung,et al.  Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  R. Mehra,et al.  The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. , 2008, Clinical advances in hematology & oncology : H&O.

[45]  A. Russo,et al.  HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  S. Spencer,et al.  Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. , 2008, International journal of radiation oncology, biology, physics.

[47]  A. Cmelak,et al.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.

[48]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[49]  J. Grandis,et al.  Epidermal growth factor receptor biology in head and neck cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A. Garden,et al.  Phase III Trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[52]  M. Goldwasser,et al.  Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[54]  S. Franceschi,et al.  Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review , 2005, Cancer Epidemiology Biomarkers & Prevention.

[55]  J. Jacobs,et al.  Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. , 2004, The New England journal of medicine.

[56]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[57]  Paula R Williamson,et al.  Aggregate data meta‐analysis with time‐to‐event outcomes , 2002, Statistics in medicine.

[58]  W. Dörr,et al.  Consequential late effects in normal tissues. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[59]  R H Wheeler,et al.  Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[61]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[62]  D. Tweardy,et al.  Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells , 1997, Oncogene.

[63]  B. Gusterson,et al.  Over‐expression of the EGF receptor is a hallmark of squamous cell carcinomas , 1986, The Journal of pathology.